Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2023-504384-16-00 | Other Identifier | EMA |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| MERCK SHARP & DOHME DE ESPAÑA S.A. | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The goal of this quasi-experimental multicenter before-after cohort study, phase II study is to evaluate the efficacy of 12-month letermovir prophylaxis in lung transplant recipients (D+/R-) compared to a historical cohort of lung transplant recipients (D+/R-) who received 12 months of valganciclovir prophylaxis to prevent CMV disease."
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Letermovir (prospective cohort) | Experimental | 2 tablets of 240 milligrams (mg) Letermovir orally once daily. during 12 months |
|
| Valganciclovir (retrospective cohort) | No Intervention | Retrospective cohort, of patients treated with Valganciclovir during 12 months |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Letermovir 240 mg Oral Tablet | Drug | Treatment will commence as soon as subjects can receive oral medication, with a maximum timeframe of 28 days after transplantation. If patients cannot receive oral medication after transplantation, initial prophylaxis with ganciclovir per clinical practice will be allowed. Medication will be discontinued 12 months after treatment initiation. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of CMV disease/replication | CMV replication: The term 'replication' can be used to indicate evidence of multiplication and is sometimes used interchangeably with CMV infection CMV disease: It is defined as symptomatic replication or invasive disease of organs or tissues that requires treatment at the investigator's discretion." | During 12 months after initiation of prophylaxis |
| Measure | Description | Time Frame |
|---|---|---|
| Antiviral prophylaxis received: | Doses administered of Letermovir or Valganciclovir | During 12 months after initiation of prophylaxis |
| Dose of non anti-viral CMV Medications: Any non-antiviral therapy received as standard of care (SoC) for the management of CMV (e.g., immunoglobulins) |
Not provided
Inclusion Criteria (prospective cohort):
Exclusion Criteria (prospective cohort):
Inclusion Criteria (retrospective cohort):
Exclusion Criteria (retrospective cohort):
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jose C Garrido Gracia, Ph.D | Contact | +34677906567 | josecarlos.garrido@imibic.org |
| Name | Affiliation | Role |
|---|---|---|
| Julián C De la Torre Cisneros, MD | Hospital Universitario Reina Sofia de Cordoba | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Universitario Reina Sofia | Córdoba | Córdoba | 14004 | Spain |
Not provided
Clinical trial of a prospective cohort compared to a retrospective (historical control) cohort.
Not provided
Not provided
Not provided
Not provided
|
Drug Dose (mg/hour) |
| During 12 months after initiation of prophylaxis |
| Administration route of non-antiviral CMV Medications: Any non-antiviral therapy received as standard of care (SoC) for the management of CMV (e.g., immunoglobulins) | Drug Administration Route | During 12 months after initiation of prophylaxis |
| Duration of treatment of non-antiviral CMV Medications: Any non-antiviral therapy received as standard of care (SoC) for the management of CMV (e.g., immunoglobulins) | Drug treatment duration (days) | During 12 months after initiation of prophylaxis |
| Discontinuation of non-antiviral CMV Medications: Any non-antiviral therapy received as standard of care (SoC) for the management of CMV (e.g., immunoglobulins) | Drug Reason for Discontinuation | During 12 months after initiation of prophylaxis |
| Reduction of the antiviral dose related to CMV antiviral toxicity | Number of events of reduction | During 12 months after initiation of prophylaxis |
| Substitution of letermovir by intravenous ganciclovir or foscarnet IV, related to CMV antiviral toxicity | Number of substitutions | During 12 months after initiation of prophylaxis |
| Dose changes of immunosuppressive therapy related to CMV antiviral toxicity | Number of changes | During 12 months after initiation of prophylaxis |
| Changes of immunosuppressive therapy related to CMV antiviral toxicity | Number of changes | During 12 months after initiation of prophylaxis |
| Use of granulocyte colony-stimulating factors (G-CSF). | Number of events (use) | During 12 months after initiation of prophylaxis |
| Incidence of leucopenia | Incidence of leucopenia. (leucopenia will be considered if the total leukocyte count is less than 3,000/mL) | During 12 months after initiation of prophylaxis |
| Incidence of neutropenia | Incidence of leucopenia. (neutropenia will be considered if the total neutrophil count is less than 1,000/mL) | During 12 months after initiation of prophylaxis |
| Hospital readmission associated with CMV complication | Number of events | During 12 months after initiation of prophylaxis |
| Incidence of viral, bacterial, or opportunistic fungal infections during the study follow-up period. | Number of events | During 12 months after initiation of prophylaxis |
| Incidence of renal toxicity directly related to CMV antivirals. | Number of events | During 12 months after initiation of prophylaxis |
| ID | Term |
|---|---|
| D003586 | Cytomegalovirus Infections |
| ID | Term |
|---|---|
| D006566 | Herpesviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| C000588473 | letermovir |
| D013607 | Tablets |
| ID | Term |
|---|---|
| D004304 | Dosage Forms |
| D004364 | Pharmaceutical Preparations |
Not provided
Not provided